arrow
Z

Zoran Andrić

us oncology network
H指数:22
被引数:3,792

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)

全外显子组测序(WES)分析来自IMpower133和IMbrella A研究6年(y)总生存期(OS)的数据,来自接受阿替利珠单抗(atezo)治疗的广泛期小细胞肺癌(ESSCLC)患者(pts)。

2024-12-011
PRE
Frontline vaccination with the B-cell peptide compound HER-Vaxx (IMU-131), combined with standard-of-care chemotherapy induces high levels of HER2-specific antibodies mediating ADCC and intracellular phosphorylation inhibition resulting in overall survival benefit in patients with HER2+metastatic or advanced gastric/GEJ adenocarcinoma - Final results from Phase II/HERIZON study
2024-04-050
PRE
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

Avelumab联合西妥昔单抗和化疗作为晚期鳞状非小细胞肺癌患者的一线治疗

2023-02-011
OA
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

阿特珠单抗与化疗治疗高血液肿瘤突变负荷的晚期或转移性NSCLC: BFAST队列C随机3期试验的初步分析

2022-08-2263
OAAI
ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
2022-02-157
PRE
A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer
2021-09-015
OAAI
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021-04-2919
OAAI
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

在接受拓扑替康治疗的小细胞肺癌患者中使用Trilaciclib进行骨髓保留: 一项随机,双盲,安慰剂对照的II期研究的结果

2020-10-2996
OAAI
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
2020-10-011.1K
OA
IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC
2020-04-156
OAAI